ResearcherLyon 1 UniversitéNo recent work listed
Julien Péron
Matched on ORCID iD 0000-0002-1709-5152; OpenAlex author ID A5001985433. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper
Papers 3
- The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001234↗
- An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.12761↗
- Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. Co-author DOI 10.1038/bjc.2015.55↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marc E Buyse · 3 shared papers, 2015–2019 · strength 0.25
- Paper The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. DOI 10.1097/mpa.0000000000001234↗
- Paper Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreati… DOI 10.1038/bjc.2015.55↗
- Paper An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. DOI 10.18632/oncotarget.12761↗
- Wendy R. Parulekar · 1 shared paper, 2015 · strength 0.06
- S. Gourgou-Bourgade · 1 shared paper, 2016 · strength 0.06
- Marc Ychou · 1 shared paper, 2016 · strength 0.06
- Thierry Conroy · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.